Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.67 |
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | CA7 | P43166 | 3/20 | 0.67 |
| ▸ | CA9 | Q16790 | 3/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | CES2 | O00748 | 1/20 | 0.62 |
| ▸ | GALR3 | O60755 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | GSTA1 | P08263 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30362168 | 1.00 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29784278 | 0.86 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12311622 | 0.85 | HPGD (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1378325 | 0.85 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29773857 | 0.84 | NR4A2 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4577829 | 0.84 | NR4A2 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2892460 | 0.83 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL861495 | 0.82 | PTPN2 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2482051 | 0.82 | NR4A2 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL25028 | 0.81 | HPGD (0.58) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 621 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119978697-A | Preparation method of high-temperature-resistant ABS material | 惠州市聚创新材料科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-110713676-A | Preparation process of wear-resistant power tube based on PVC material | 安徽瑞琦塑胶科技有限公司 | 2020-01-21 | — | — | CN | claimed |
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| CN-122010913-A | Rhodamine-marked isoquinoline derivative and preparation method and application thereof | 淮阴师范学院 | 2026-05-12 | — | — | CN | disclosed |
| US-12595239-B2 | Substituted isoxazoline derivatives | BASF SE (DE) | 2026-04-07 | — | — | US | disclosed |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2026-01-08 | — | — | US | disclosed |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2025-11-06 | — | — | US | disclosed |
| US-12435047-B2 | c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250268903-A1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-08-28 | — | — | US | disclosed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-4634768-A | INTERMEDIATES FOR VASODILATORS | YAMAMOTO CHEMICAL INDUSTRIAL CO., LTD. (JP) | 1987-01-06 | — | — | US | disclosed |
| US-4570006-A | ANTITHROMBIN; ENZYME AND HORMONE INHIBITORS | TORII & CO. LTD. (JP) | 1986-02-11 | — | — | US | disclosed |
| EP-0105484-B1 | 3-PROPIONYLSALICYCLIC ACID DERIVATIVES AND PROCESS FOR THE PREPARATION OF THE SAME | Yamamoto Chemical Industrial Company, Limited (JP) | 1986-01-15 | — | — | EP | disclosed |
| US-4533732-A | CHEMICAL INTERMEDIATES TO PRODUCTION OF FLAVONES | YAMAMOTO CHEMICAL INDUSTRIAL COMPANY, LIMITED (JP) | 1985-08-06 | — | — | US | disclosed |
| US-4514416-A | Amidine compound, process for producing same and anti-complement agent comprising same | TORII & CO. LTD. (JP) | 1985-04-30 | — | — | US | disclosed |
| EP-0107804-A1 | 3-Methylflavone-8-carboxylic acid derivatives and process for the preparation of the same | Yamamoto Chemical Industrial Company, Limited (JP) | 1984-05-09 | — | — | EP | disclosed |
| EP-0105484-A2 | 3-Propionylsalicyclic acid derivatives and process for the preparation of the same | Yamamoto Chemical Industrial Company, Limited (JP) | 1984-04-18 | — | — | EP | disclosed |
| US-4420476-A | Benzofuro[3,2-c]pyrazol-3-amine derivatives | Averst McKenna & Harrison, Inc. (CA) | 1983-12-13 | — | — | US | disclosed |
| US-3993852-A | DIALKYL PHENYLALKANEPHOSPHONATES | CIBA-GEIGY AG (CH) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | F11, F13B, F7 | CA12 2665/4885CA1 2410/4885CA2 1177/4885 |
| US-12435047-B2 | c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | ABL1, ABL2, MUSK | CA12 3929/4885CA1 2508/4885CA2 1670/4885 |
| US-12595239-B2 | Substituted isoxazoline derivatives | CBR3, ADRA2C, CYP4Z1 | CA12 2451/4885CA1 2085/4885CA2 1520/4885 |
| US-20260008770-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | CBL, CBLC, CBLB | CA12 4302/4885CA1 3836/4885CA2 2201/4885 |
| US-20250268903-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | CA12 4434/4885CA1 4736/4885CA2 3556/4885 |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | CA12 3929/4885CA1 2508/4885CA2 1670/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | CA12 4808/4885CA1 4853/4885CA2 4637/4885 |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BCL6B | CA12 964/4885CA1 1157/4885CA2 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.